Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

• Melissa Dumble,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Ming-Chih Crouthamel,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Shu-Yun Zhang,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Michael Schaber,

  Affiliation Platform Technology & Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Dana Levy,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Kimberly Robell,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Qi Liu,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• David J. Figueroa,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Elisabeth A. Minthorn,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Mark A. Seefeld,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Meagan B. Rouse,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Sridhar K. Rabindran,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Dirk A. Heerding,

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Rakesh Kumar

  * E-mail: rakesh.2.kumar@gsk.com

  Affiliation Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯